Our lab is interested in mechanisms that cause cell death in neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS), frontotemporal dementia (FTD), and Alzheimer's disease (AD) disorders. The work focuses on cell cycle dysfunction, apoptosis, mitochondrial impairment, oxidative damage, and proteostasis using in vivo models of neurodegeneration and in vitro culture of cells, including peripheral cells from patients.

A collection of lymphoblastoid cell lines from patients with these disorders is being updated to include genetically well characterized cases of ALS and FTD. We are using lymphoblasts from patients to test the therapeutic potential of certain drugs impacting impaired signaling cascades in ALS and FTD, and particularly the effects of inhibiting TDP-43 phosphorylation in the treatment of the ALS/FTD spectrum. The effects of novel Casein kinase 1- d) (CK-1 d) CDC7 inhibitors, and the GSK-3b inhibitor Tideglusib are currently being studied 

 

Publications

CNS Drugs. 2018 May 7. doi: 10.1007/s40263-018-0515-7; Sci Rep. 2017 May 10;7(1):1666; Mol Neurobiol. 2017 54:5683­5698; Mol Neurodegener. 2016 Apr 30;11(1):36. 1750-1326; Curr Alzheimer Res. 2016;13(4):439­49.; Mol Neurobiol. 2015;52(1):386­98; Mol Neurobiol 2016 Dec;53(10):7107-7118; Mol Neurobiol. 2015;52(3):1714­25; J Psychiatry Neurosci. 2015;41(1):150131. 1180-4882; Eur Neuropsychopharmacol. 2015 Mar;25(3):386-403.; Alzheimers Dis. 2015;46(2):329­50

 

 
     

TEAM

Ángeles Martín Requero

Gracia Porras Franco

 

 

 

CONTACTO:


 


 

 Coordinadora:

Ana Martínez (This email address is being protected from spambots. You need JavaScript enabled to view it.)

Gestora del Proyecto:

Nuria Mª Rivas (This email address is being protected from spambots. You need JavaScript enabled to view it.)

Centro de Investigaciones Biológicas (CIB-CSIC)

C/Ramiro de Maeztu, 9

28006 MADRID

 

 

 

 

 

 

             Proyecto ELA-MADRID.B2017/BMD-3813

 

 Proyecto financiado por la Comunidad de Madrid y la Unión Europea